Literature DB >> 27170615

Systemic BCG infection in a patient with pancytopaenia and fever 9 years after intravesical BCG administration for bladder cancer.

Ine M Westhovens1, Marie-Elena Vanden Abeele1, Peter E Messiaen2, Jeroen Ch van der Hilst3.   

Abstract

BCG is an attenuated live strain of Mycobacterium bovis that is used as an intravesical immunotherapy for superficial bladder cancer. Although generally well tolerated, BCG instillation can lead to systemic diseases. We present a case of a 75-year-old man who was treated for recurrent localised transitional cell carcinoma (TCC) of the bladder with intravesical instillation of BCG in 2006. His medical history included Parkinson's disease. The patient reported worsening of Parkinson symptoms in the preceding month. In addition, he had progressive pancytopaenia and a bone marrow biopsy showed a granulomatous inflammatory infiltrate. Cultures from bone marrow aspiration grew M. bovis He was successfully treated with tuberculostatic drugs and made a full recovery. In addition, there was partial amelioration of the Parkinson symptoms. This case shows that physicians should be aware that BCG instillation for TCC can cause systemic disease even years after treatment. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27170615      PMCID: PMC4885450          DOI: 10.1136/bcr-2016-215599

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  6 in total

1.  [Complications of endovesical treatment with BCG in a series of 200 patients].

Authors:  L E Resel Folkersma; J A Belón Lopéz Tomasetti; S Isorna Martínez de la Riva; J A Caminero Luna
Journal:  Arch Esp Urol       Date:  1999-11       Impact factor: 0.436

2.  Tuberculous epididymo-orchitis after intravesical BCG therapy for superficial bladder carcinoma: sonographic findings.

Authors:  Rafael Salvador; Ramon Vilana; Xavier Bargalló; Xavier Araque; Carlos Nicolau
Journal:  J Ultrasound Med       Date:  2007-05       Impact factor: 2.153

3.  Systemic bacillus Calmette-Guérin infection, 'BCGitis', in patients treated by intravesical bacillus Calmette-Guérin therapy for bladder cancer.

Authors:  A Steg; C Leleu; B Debré; L Boccon-Gibod; D Sicard
Journal:  Eur Urol       Date:  1989       Impact factor: 20.096

Review 4.  Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.

Authors:  Koji Kawai; Jun Miyazaki; Akira Joraku; Hiroyuki Nishiyama; Hideyuki Akaza
Journal:  Cancer Sci       Date:  2013-01-03       Impact factor: 6.716

5.  Late Mycobacterium bovis spondylitis after intravesical BCG therapy.

Authors:  Andreas F Mavrogenis; Vasileios I Sakellariou; Sotirios Tsiodras; Panayiotis J Papagelopoulos
Journal:  Joint Bone Spine       Date:  2009-03-19       Impact factor: 4.929

Review 6.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

  6 in total
  2 in total

1.  Case Report: Acquired Disseminated BCG in the Context of a Delayed Immune Reconstitution After Hematological Malignancy.

Authors:  Vincent Gies; Yannick Dieudonné; Florence Morel; Wladimir Sougakoff; Raphaël Carapito; Aurélie Martin; Noëlle Weingertner; Léa Jacquel; Fabrice Hubele; Cornelia Kuhnert; Sophie Jung; Frederic Schramm; Pierre Boyer; Yves Hansmann; François Danion; Anne-Sophie Korganow; Aurélien Guffroy
Journal:  Front Immunol       Date:  2021-08-03       Impact factor: 7.561

2.  Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.

Authors:  Tara Rachakonda; Brian Kendall; Adam M Spivak; Jonathan Boltax
Journal:  Open Forum Infect Dis       Date:  2017-06-17       Impact factor: 3.835

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.